Dr. Anusha Sunder*

Doctorate in Life Science/Human Nutrition, Accredited Certification in Nutrigenetics; Lead Scientist and Nutrigenetic Expert, Xcode Life Sciences, Pvt. Ltd. Chennai, India

*Corresponding Author: Dr. Anusha Sunder, Doctorate in Life Science/Human Nutrition, Accredited Certification in Nutrigenetics; Lead Scientist and Nutrigenetic Expert, Xcode Life Sciences, Pvt. Ltd. Chennai, India.

Received: May 14, 2024; Published: June 27, 2024

Abstract

The current strategies of immunosuppression and prophylactic antimicrobial medication in a transplantation are exemplary. Still the desirable outcome of relief from rejection and infection risk aren’t a guarantee! Graft survival relies not just on human leukocyte antigen matching, other crucial factors include the infection risk, extent of immunosuppression, and management of comorbidities. The transplant outcome can be improved through risk stratification of genetic predispositions and application of precision pharmacotherapy.

 Keywords: Transplant Outcome; Transplant Donor; Transplant Recipient; Immunosuppression; Graft Survival; Graft Rejection; Genetic Predictors; Single Nucleotide Polymorphisms/SNPs; Precision Medicine

References

1. Nobakht E., et al. “Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?”. Transplant Direct2 (2021): e650.
2. Yang JY and Sarwal MM. “Transplant genetics and genomics”. Nature Reviews Genetics5 (2017): 309-326.
3. Giannoukakis N., et al. “Gene therapy in transplantation”. Gene Therapy 6 (1999): 1499-1511.
4. Hernandez A and Evers BM. “Functional Genomics: Clinical Effect and the Evolving Role of the Surgeon”. Archives of Surgery11 (1999): 1209-1215.
5. Cruz-Tapias P., et al. “Major histocompatibility complex: Antigen processing and presentation”. In: Anaya JM, Shoenfeld Y, Rojas-Villarraga A, et al., editors. Autoimmunity: From Bench to Bedside [Internet]. Bogota (Colombia): El Rosario University Press (2013). Chapter 10.
6. Priyadharshini B., et al. “T-cell activation and transplantation tolerance”. Transplantation Reviews (Orlando). 3 (2012): 212-222.
7. Phelan PJ., et al. “Genetic determinants of renal transplant outcome: where do we stand? Journal of Nephrology3 (2014): 247-256.
8. Chand S., et al. “Genetic polymorphisms and kidney transplant outcomes”. Current Opinion in Nephrology and Hypertension 6 (2014): 605-610.
9. Eikmans M., et al. “The functional polymorphism Ala258Ser in the innate receptor gene ficolin-2 in the donor predicts improved renal transplant outcome”. Transplantation5 (2012): 478-485.
10. Qiu XY., et al. “Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients”. Nephrology (Carlton)4 (2012): 423-430.
11. Wu Z., et al. “FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients”. European Journal of Clinical Pharmacology1 (2017): 39-47.
12. Shrestha BM. “Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences”. Experimental and Clinical Transplantation 1 (2017): 1-9.
13. Xu QX., et al. “FOXP3 rs3761549 polymorphism predicts long-term renal allograft function in patients receiving cyclosporine-based immunosuppressive regimen”. Gene 644 (2018): 93-100.
14. Khuja Z., et al. “Association of Forkhead Box P3 Gene Polymorphisms With Allograft Rejection Episodes in Kidney Transplant Patients: a Study From Kashmir, North India”. Iranian Journal of Kidney Diseases 5 (2018): 305-311.
15. Xu Q., et al. “NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients”. Pharmacogenomics4 (2017): 381-392.
16. Wu Z., et al. “FKBP1A rs6041749 polymorphism is associated with allograft function in renal transplant patients”. European Journal of Clinical Pharmacology1 (2019): 33-40.
17. Nair SS., et al. “Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level”. Experimental and Clinical Transplantation 13 (2015): 197-200.
18. Niioka T., et al. “Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations”. Clinical and Experimental Nephrology5 (2017): 787-796.
19. Singh R., et al. “Interleukin 8 -251T>A and Interferon gamma +874A>T polymorphism: potential predictors of allograft outcome in renal transplant recipients from north India”. Transplant Immunology1 (2009): 13-17.
20. Duan Z., et al. “Association between CTLA4 gene polymorphisms and acute rejection of kidney transplantation: a meta-analysis’. Journal of Nephrology6 (2012): 996-1002.
21. Gao JW., et al. “A deeper understanding of the association between CTLA4 +49A/G and acute rejection in renal transplantation: an updated meta-analysis”. Ren Fail1 (2015): 165-174.
22. Yang CH., et al. “Association of cytotoxic T-lymphocyte antigen 4 +49A/G gene polymorphism with acute rejection risk in renal transplantation”. Pediatric Transplantation4 (2017).
23. Singh R., et al. “Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in North Indian renal transplant recipients”. Scandinavian Journal of Immunology 1 (2009): 51-56.
24. Omrani MD., et al. “Association of CCR5-59029 A/G and CCR2-V64I variants with renal allograft survival”. Iranian Journal of Immunology4 (2008): 201-206.
25. Firasat S., et al. “The effect of chemokine receptor gene polymorphisms (CCR2V64I, CCR5-59029G>A and CCR5Δ32) on renal allograft survival in Pakistani transplant patients”. Gene2 (2012): 314-319.
26. Cha RH., et al. “Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5”. Nephrol Dial Transplant 9 (2009): 2919-2925.
27. Hu X., et al. “Donor or recipient TNF-A -308G/A polymorphism and acute rejection of renal allograft: A meta-analysis”. Transplant Immunology1 (2011): 61-71.
28. Lv R., et al. “Association between IL-6 -174G/C polymorphism and acute rejection of renal allograft: evidence from a meta-analysis”. Transplant Immunology1 (2012): 11-18.
29. Kocierz M., et al. “174G/C interleukin-6 gene polymorphism and the risk of transplanted kidney failure or graft loss during a 5-year follow-up period”. Tissue Antigens4 (2011): 283-290.
30. Wu W., et al. “Association between IL-4 polymorphism and acute rejection of solid organ allograft: a meta-analysis”. Gene1 (2013): 14-21.
31. Ge YZ., et al. “Association between transforming growth factor beta-1 +869T/C polymorphism and acute rejection of solid organ allograft: A meta-analysis and systematic review”. Transplant Immunology2-3 (2014): 76-83.
32. Park JY., et al. “TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans”. Tissue Antigens6 (2004): 660-666.
33. Salido E., et al. “The PlA2 polymorphism of the platelet glycoprotein IIIA gene as a risk factor for acute renal allograft rejection”. Journal of the American Society of Nephrology 12 (1999): 2599-2605.v
34. Luo Y., et al. “Elevated Circulating IL-10 Producing Breg, but Not Regulatory B Cell Levels, Restrain Antibody-Mediated Rejection After Kidney Transplantation”. Frontiers in Immunology 11 (2021): 627496.
35. Elias C., et al. “Regulatory B Cells in Solid Organ Transplantation: From Immune Monitoring to Immunotherapy”. Transplantation 5 (2024): 1080-1089.

Citation

Citation: Dr. Anusha Sunder. “Genes Govern the Acceptance or Rejection of a Transplant!”.Acta Scientific Medical Sciences 8.7 (2024): 230-242.

Copyright

Copyright: © 2024 Dr. Anusha Sunder. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.